Improved understanding of the interactions between cancer cells and the immune system combined with technological advances has led to the development of novel types of immunotherapies. These include checkpoint inhibitors, T-cell engager antibodies and chimeric antigen receptor T cells which have demonstrated remarkable efficacy in B-cell malignancies, including anti-PD1 antibodies in Hodgkin lymphoma, and T-cell engager antibodies and chimeric antigen receptor T cells in B-cell acute lymphoblastic leukemia, leading to their approval in these indications. Recent clinical data suggest that these immunotherapies may also benefit patients with other types of hematologic malignancies, particularly patients with Hodgkin and non-Hodgkin lymphomas. Here, we review the most recent clinical data regarding these different immunotherapies in patients with lymphoma. Ongoing and future studies should further define which immunotherapy may best apply to a given patient in order to provide a 'personalized immunotherapy'.
Introduction
The complex relationship between the immune system and cancer development has been the subject of investigation for decades. In recent years, crucial advances have been made in this field. This progress, combined with technological advances, has led to the development of novel immunotherapies which have demonstrated remarkable efficacy for the treatment of cancer. In lymphoid malignancies, three of these new immunotherapies appear to be particularly promising: immune checkpoint inhibitors (CPI), Tcell engager antibodies (TCE) and chimeric antigen receptor (CAR)-T cells. Each of these approaches has its own advantages and inconveniences (Table 1) . Some of these immunotherapies have already been granted approval by the Food and Drug Administration (FDA) for hematologic malignancies [anti-PD1 antibodies (Abs) in Hodgkin lymphoma (HL), TCE and CAR-T cells in B-cell acute lymphoblastic leukemia (B-ALL)]. In the future, these approvals are likely to be extended to other malignancies, including HL and non-Hodgkin lymphoma (NHL). In this review, we analyze the most recent clinical data regarding these different immunotherapies in patients with lymphoma.
Checkpoint inhibitors
CPI are monoclonal Abs that block T-cell inhibitory signals. They can 'reinvigorate' a pre-existing antitumor immune response by releasing the breaks from tumor immunosuppression. These therapies are unique because they do not target directly the tumor cells but rather the immune system. This explains why the same CPI may be used for the treatment of various cancers. To date, six CPI have been approved by the FDA for the treatment of cancer: one anti-CTLA4 Ab (ipilimumab), two anti-PD1 Abs (nivolumab, pembrolizumab) and three anti-PDL1 Abs (atezolizumab, avelumab and durvalumab).
These CPI exhibit toxicities which are different from those observed with chemotherapy or other antitumor agents. These toxicities are characterized by the occurrence of immune-related adverse events (irAEs) which are frequent (up to 90% of patients) although usually mild. However, in some cases, these irAEs may be severe and sometimes life-threatening, particularly with anti-CTLA4 Abs (5%-20% of grade ! 3 adverse events in monotherapy) [1] . Luckily, most of these irAEs are reversible although some may be definitive (e.g. endocrine disorders). Following encouraging results on solid tumors, these CPI were also evaluated in patients with lymphoma (Table 2) .
Hodgkin lymphoma
To date, HL is the most sensitive cancer to anti-PD1 Abs. This may be explained by the fact that the Reed-Sternberg cells (RSC) constantly express the ligand for PD1 (PD-L1 ligand). This constitutive expression of PD-L1 may result from two mechanisms: (i) genetic alterations in 9p24 which are found in 97% of RSC in HL [2] . This amplicon contains the PD-L1 and PD-L2 genes which are then directly amplified and overexpressed. It also contains the JAK2 gene which, indirectly, also induces the transcription of the PDL1 and PDL2 genes; and (ii) Epstein-Barr virus (EBV) infection (present in about 40% of HL tumors) induces PD-L1 expression via the viral protein LMP1 [3] . Interestingly, some clinical evidence suggests a positive correlation between the level of PD-L1 expression by the RSC and the efficacy of nivolumab in HL patients [4] . However, the mechanism of action of anti-PD1 Abs in HL remains incompletely elucidated as the RSC have frequently lost the expression of class I (usually by loss/ mutation of the b2 microglobulin gene [5] ) and/or class II human leukocyte antigen (HLA), theoretically compromising their recognition by T cells [6] [7] [8] .
The first trials evaluating anti-PD1 Abs in HL were carried out on small numbers of patients (23 and 31 patients, respectively). All these patients had been heavily pretreated [the majority of them had received prior treatment with brentuximab vedotin (BV) and/or autologous hematopoietic stem-cell transplantation (HSCT)]. Nevertheless, the results were dramatic, showing tumor regression in almost all patients [9, 10] . These results were confirmed in a study which evaluated nivolumab in 80 HL patients who had relapsed after autologous HSCT and BV [4] . To date, the two largest studies testing anti-PD1 Abs in HL are CHECKMATE-205 (N ¼ 243 patients treated with nivolumab) [11] and KEYNOTE-087 (N ¼ 210 patients treated with pembrolizumab) [12] . These studies, which represent more than 450 patients in total, showed overall response rates around 70% and complete remission (CR) rates around 20%. There appear to be no clear differences in efficacy according to the treatments previously received (BV and/or autologous HSCT) or between nivolumab and pembrolizumab (provided these studies were not meant to be comparative). These results led to the approval by the FDA of nivolumab and pembrolizumab in relapsed or refractory HL in May 2016 and March 2017, respectively. Although the response rates to anti-PD1 are very important in HL, a significant proportion of patients seem to escape secondarily, particularly those who have not reached a CR. Indeed, the latest results of CHECKMATE-205 study showed that for patients in CR, the median duration of response was not reached after a median follow-up of 15 months whereas for patients in partial response (PR), the median duration of response was 13 months (cohort B) [13] . The question therefore arises whether, in these patients, the treatment with anti-PD1 should be continued (for how long?) exposing the patients to the risk of tumor escape and progression, or whether these patients should be consolidated with an allogenic HSCT exposing the patients to an increased risk of toxicities. Indeed, a non-comparative, retrospective study by Merryman et al. suggested that patients undergoing allogenic HSCT who had been previously treated with anti-PD1 Abs might experience more toxicities compared with historical controls, notably a possible increased risk of sinusoidal obstruction syndrome (SOS) and acute graft-versus-host disease (aGVHD), sometimes fatal [14] . A significant proportion of patients also developed a 'non-infectious febrile syndrome'. Interestingly, relapse rates appeared to be lower in patients who have received anti-PD1 treatment before allogenic HSCT compared with historical controls. In a recent publication by Beköz et al., 11 patients treated by nivolumab received allogenic HSCT. Three patients developed skin GVHD, one patient experienced chronic lung GVHD, and two patients died [15] . Two studies focused on patients treated with anti-PD1 after allogenic HSCT [16, 17] . These studies showed that treatment with anti-PD1 may cause or reactivate GVHD. These GVHDs usually occur early (i.e. within weeks), are often steroid-refractory and are accompanied by a high mortality rate. However, the antitumor efficacy of anti-PD1 after allogenic HSCT seems very good with objective 
HSCT, hematologic stem-cell transplantation; NHL, non-Hodgkin lymphoma; CLL, chronic lymphoid leukemia; DLBCL, diffuse large B-cell lymphoma; PMBL, primary mediastinal B-cell lymphoma; MF/SS, mycosis fungoid/Sezary syndrome; FL, follicular lymphoma; PCNSL, primary central nervous system lymphoma; RS, Richter syndrome; pts, patients; ORR, overall response rate; CR, complete response; PR, partial response; SD, stable disease; HL, Hodgkin lymphoma; HSCT, hematopoietic stem-cell transplantation, BV, brentuximab vedotin.
response rates comprised between 79% and 95% (including 42%-50% complete responses) and prolonged PFS. Thus, PD-1 blockade before or after an allogenic HSCT may be associated with an increased toxicity and efficacy. However, the data available in these situations remain very limited and one should be very cautious not to draw premature conclusions. More studies are needed to better determine how these two therapies may be optimally combined (and define in which order) and how their toxicities should be better managed.
Avelumab is an anti-PDL1 Ab which function is substantially different from anti-PD1 Abs. This Ab is directed against the tumor cells (and the PDL1-expressing immunosuppressive cells from the microenvironment) in order to block the PD1-PDL1 interaction. In vitro, avelumab induces Ab-dependent cellular cytotoxicity via its IgG1 constant domain. Additionally, it does not block the interaction between PD1 and its other ligand, PDL2. Avelumab's efficacy in HL may be reduced compared with anti-PD1 Abs due to (i) the absence of PDL2 blockade and (ii) its short half-life (6 versus %26 days for nivolumab and pembrolizumab). A preliminary phase Ib trial testing avelumab in 31 patients with relapsed/refractory HL showed an overall response rate of 42%, including 16% complete responses [18] . Two other anti-PDL1 Abs are also being tested in lymphoma: atezolizumab in monotherapy in patients with relapsed or refractory HL (NCT03120676) and durvalumab in monotherapy (NCT03241017) and in combination (Table 3) in patients with NHL.
Numerous combination studies are also in progress to improve or prolong anti-PD1 efficacy ( Table 3 ). The immunologic rationale for combining them with other anticancer agents is described in Table 7 . In particular, two studies are testing the combination of nivolumab and BV. Intermediate results of these studies were reported at ICML 2017 [19, 20] and one was recently published [21] . In these studies, complete response rates were particularly high (61% and 63%, respectively). Another study (CheckMate 039) tested the combination of nivolumab and ipilimumab [22] . Of the 31 patients with HL, the overall response rate was 74%, including 19% CR. These results are substantially similar to what is expected with nivolumab monotherapy.
Non-Hodgkin lymphomas
Checkpoint inhibitors were also tested in NHLs, including anti-CTLA4 and anti-PD1 Abs (Table 2) . A dose escalation phase I trial evaluated ipilimumab (anti-CTLA4) in patients with refractory or relapsed NHL. Among 18 patients, there were two objective responses: one PR in a patient with follicular lymphoma and one prolonged CR (ongoing at 31 months) in a patient with diffuse large B-cell lymphoma (DLBCL) [23] . Ipilimumab was also tested in 29 cancer patients who had relapsed after an allogenic HSCT. Patients received one injection of ipilimumab at a dose of 0.1-3 mg/kg [24] . Among patients with lymphoid malignancies, two CRs (two HL) and one PR (one mantle cell lymphoma) were observed. No response was observed in patients with chronic lymphocytic leukemia (CLL) (N ¼ 2) nor myeloma (N ¼ 6). Another study tested repeated and higher doses (3 and 10 mg/kg) of ipilimumab in patients with hematologic malignancies who had relapsed after allogeneic-HSCT [25] . Among patients who received ipilimumab at 10 mg/kg (N ¼ 22), there were five CRs (four AML and one MDS), two PR (one HL and one plasmacytoma) and six tumor regressions (two AML, three HL and one T-NHL). Of note, six patients (21%) experienced GVHD.
The anti-PD1 Ab, nivolumab, was evaluated in 81 patients with relapsed or refractory lymphoid malignancies, including 10 follicular lymphoma and 11 DLBCL [26] . In these patients, the overall response rates were 40% (one CR and three PRs) and 36% (two CRs and two PRs), respectively. However, these results need to be interpreted with caution due to the very small number of patients. The ongoing phase II trial, Checkmate-139, should help clarify the actual efficacy anti-PD1 Abs in DLBCL.
Interestingly, some subsets of NHL may be particularly sensitive to anti-PD1 therapy. These include NHL with 9p24 genetic alterations (which is not restricted to HL) and lymphomas which are associated with EBV, which frequently express PDL1 [27] . The 9p24 genetic alterations can be found in about half of the primary mediastinal B-cell lymphomas (PMBL), primary central nervous system (CNS) lymphomas and testicular lymphomas whereas it is found in only 6% of DLBCL [28] . KEYNOTE-013 (NCT01953692) evaluated the efficacy of pembrolizumab (anti-PD1) in PMBL [29] . In this study, the overall response rate was 41% (7/17 patients). These results led to an extended multicenter phase II study (KEYNOTE-170, NCT02576990) in which intermediate results were presented at ICML 2017. Among 29 assessable patients, the overall response rate was 41% including four complete responses (14%) [30] . Another anti-PD1, nivolumab was also tested in a small series of five patients with relapsed or refractory primary CNS lymphoma (N ¼ 4) or testicular lymphoma with CNS relapse (N ¼ 1) [31] . All patients experienced an objective response, including four CRs, three of whom remained progression-free at 13þ to 17þ months. These data suggest that immunotherapy may also be effective in so-called 'immuno-privileged' sites.
Pembrolizumab was tested in 25 patients with relapsed or refractory CLL (N ¼ 16) or Richter syndrome (RS) (N ¼ 9) [32] . None of CLL patients responded but four out of nine RS patients (44%) experienced an objective response including one CR. RS may be particularly sensitive to anti-PD1 therapy because it is known to have a high degree of genetic instability (%50% TP53 disruption) and an increased expression of PDL1.
Anti-PD1 may also be effective in T-NHL although one may be concerned about a potential stimulatory effect of CPI on tumor T cells. Pembrolizumab was tested in 24 patients with relapsed or refractory mycosis fungoides or Sezary syndrome. The overall response rate was 38% (one complete response and eight PRs) [33] . A 'skin-flare' reaction was observed in some patients (8/15, all Sezary syndrome), which did not correlate with tumor response nor progression. NK/T lymphomas may also respond to PD1-blockade. This lymphoma is constantly associated with EBV and its prognosis is poor in case of relapse after treatment with L-asparaginase (median overall survival ¼ 3-4 months). Pembrolizumab was initiated in seven patients with relapsed or refractory T/NK lymphoma. All patients experienced an objective response, including five CRs [34] .
Similar to HLs, numerous combination studies are in progress in NHLs to further improve these results (Tables 3 and 7) . Of note, trials combining anti-PD1 Abs with lenalidomide, an immunomodulatory drug, have been recently placed on hold by the FDA because of a death rate higher than expected 
T-cell engager Abs
T-cell engager Abs are immunoglobulin fragments capable of recognizing two antigens: one located on the tumor cells (e.g. CD19) and one on the T cells (e.g. CD3). This double recognition is meant to recruit and activate T cells in contact with the tumor and trigger tumor cell destruction by the T cells. Blinatumomab (Amgen V R ), an anti-CD19/CD3 bispecific Ab, was the first TCE to demonstrate efficacy in the clinic. Blinatumomab has been shown to be effective in relapsed and refractory B-ALL [35, 36] . In 2014, blinatumomab was approved by the FDA in this indication. Following these encouraging results, blinatumomab as well as other TCE have been evaluated in patients with lymphoma (Table 4) .
Non-Hodgkin lymphoma
A phase I study evaluated blinatumomab in 76 patients with relapsed or refractory B-NHL [37] . As for ALL, blinatumomab was administered in continuous infusions (over several weeks) given its very short half-life (2 h). However, the dose used in NHL was much higher than the one used in ALL (60 mg/m 2 /day versus 28 mg/day). Beyond this dose, there is a limiting neurologic toxicity. In this study, at the optimal dose, the overall response rate was 69% for all B-NHL patients (N ¼ 35) and 55% for DLBCL (N ¼ 11). A phase II study reported by Viardot et al. evaluated blinatumomab in patients with relapsed or refractory DLBCL [38] . Of the 21 assessable patients, the overall response rate was 43%, including 19% CR, some of which were prolonged. A phase II/III study is currently underway to compare blinatumomab with conventional (investigator-selected) treatment in patients with relapsed or refractory aggressive NHL in incomplete response after salvage therapy (NCT02910063). Blinatumomab is also evaluated in combination with lenalidomide in relapsed or refractory NHL (NCT02568553).
Other TCE are also being tested in NHL. REGN1979, a new CD20/CD3 bispecific TCE, was evaluated in a phase I trial. The preliminary results, presented at ASH 2016, seem to show moderate efficacy with an overall response of 20% (N ¼ 20), although dose escalation is still ongoing [39] . FBTA05 is a CD20/CD3 'trifunctional' TCE with a preserved IgG1-like constant domain. It was evaluated in a phase I/II trial in combination with donor lymphocyte infusion for the treatment of patients with NHL who had relapsed after allogenic HSCT (NCT01138579). This molecule had shown promising results in a phase I for pediatric patients with B-lymphoid malignancies (NHL, Burkitt lymphoma, ALL) 
Hodgkin lymphoma
The RSC strongly express CD30 which makes it a target of choice for Ab recognition. AFM13, a tetrameric bispecific Ab (TandAb V R ) presenting two anti-CD30 domains and two anti-CD16A domains, was developed in order to recruit and activate NK cells via FccRIII (CD16) at the tumor site. A phase I trial evaluated increasing doses of AFM13 (weekly infusions) in 26 patients with relapsed or refractory HL [41] . The overall response rate was 23% with a dose-dependent efficacy. A phase II is currently underway (NCT02321592).
CAR-T cells
CAR-T cells have been in clinical development since the late 1990s, initially in solid tumors. CAR-T cells are T cells which have been genetically modified and expanded ex vivo after apheresis. These T cells are engineered to express a CAR which allows them to be 'redirected' against the tumor cells. The chimeric receptor is a transmembrane protein composed of the Agrecognition domain of an Ab for the extracellular part, a transmembrane hinge and an intracellular activation signal (usually CD3). Several generations of CAR-T cell were tested with one and or several co-stimulatory signals (e.g. CD28, CD137, OX40) to increase T cells activation and persistence after injection to the patients. Unlike unmanipulated T cells, CAR-T cells recognize tumor cells in an Ab-dependent manner, thus with a higher affinity than TCRs and in an HLA-independent manner. In 2008, Till et al. reported the first study testing CAR-T cell in hematologic malignancies [42] . These CD20 CAR-T cells were used to treat patients with B-NHL (n ¼ 7). The results were disappointing, probably because of the short persistence of CARs in the body, despite repeated injections of IL-2. Since then, new generations of CAR-T cells combined with the use of lymphodepleting conditioning regimens have significantly improved these results. CARs directed against CD19 have shown dramatic activity in refractory or relapsed patient with acute lymphoid leukemia (up to 90% CR rate) [43, 44] and NHL, explaining the current enthusiasm for these new therapies (Table 5) . In August 2017, this first-in-class therapy (CTL019) was approved by the FDA for the treatment of children and young adults with relapse or refractory B-ALL [45] . Few months later, in October 2017, KTE-C19 was also approved by the FDA for the treatment of adults with R/R DLBCL [46] .
Non-Hodgkin lymphoma
In NHL, most CAR-T cells tested are directed against CD19 (Table 5 ). One of the first studies to report the efficacy of CD19-CARs in patients with NHL or CLL was published in 2015 [47] . Among the 15 patients, 6 out of 7 DLBCL patients experienced objective responses, including 4 CRs, and 2 out of 2 patients with indolent lymphoma experienced an objective response, including one CR. Brudno et al. reported the results of allogenic CAR-T cells in 20 patients with B-cell malignancies who had relapsed after an allogenic HSCT. Eight out of 20 patients experienced an objective response including 6 CRs without induction of GVHD [48] . A recent study demonstrated an overall response rate of 73% (including 55% CR) among 22 patients with B-NHL (mostly DLBCL, N ¼ 19) [49] . Eleven of the 12 CRs were still ongoing at the time of publication. Interestingly, the study found that high serum IL-15 levels were associated with high-peak blood CAR-Tcell levels and remissions of lymphoma.
The three most advanced CAR-T cells developed for lymphoma are CTL019 (Novartis/UPenn), JCAR (Juno/MSKCC) and KTE-C19 (Kite/NCI). These CAR-T cells differ in various ways (Table 6) . Recently, the ZUMA-1 study evaluated the efficacy of CD19 CAR-T cells (KTE-C19, Axicabtagene Ciloleucel, Axi-Cel) in 101 patients with refractory DLBCL/PMBL (defined by the lack of response to the last-line chemotherapy or relapse within a year after an auto-HSCT). According to the SCHOLAR-I study HSCT, hematologic stem-cell transplantation; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; CLL, chronic lymphoid leukemia; BiTE, bispecific T-cell engager; DLBCL, diffuse large B-cell lymphoma; pts, patients; ORR, overall response rate; CR, complete response.
(N ¼ 636 patients), these patients have an extremely poor prognosis following conventional chemotherapy with only 26% objective response, 7% CR and a median overall survival of 6.3 months [50] .
Intermediate results of the ZUMA-1 study were presented at ICML 2017 [51] and final results were recently published [52] . This study, the largest in patient with lymphoma, is remarkable for several reasons. First, it demonstrates the feasibility of large-scale, multicenter (national and soon international), CAR-T cells trials, as 22 centers participated in ZUMA-1. Furthermore, it demonstrates the ability to produce CAR-T cells in a timely manner (17 days average turnaround time from apheresis and delivery to clinical site) and efficiently (99% manufacturing success rate). The efficacy is remarkable in these patients known to have a very poor prognosis with 42% of patients responding at 15 months, 40% of whom remain in complete response after a median follow-up of 15.4 months, and a median overall survival not reached. The median duration of response was 11.1 months and was not reached for patients in complete response. At 6 months, 78% of patients were still alive (versus 55% in the SCHOLAR-I study). CTL019, another CD19 CAR-T cell, was also evaluated in patients with refractory DLBCL. Intermediate results from the JULIET study were presented at ICML 2017 [53] and ASH 2017 [54] . Analysis of 81 patients followed for at least 3 months found 53% of best objective response with 40% of complete responses. Most patients in complete response at 3 months presented ongoing response at 6 months. A third type of CD19 CAR-T cells, JCAR017, was also evaluated in NHL patients. In the TRANSCEND study, these CAR-T cells were administered with a CD4/CD8 ratio of 1 : 1 instead of a bulk of T cells in the two previous studies (ZUMA-1 and JULIET) [55, 56] . The 3-month analysis showed an overall response of 53%, including 44% CR, among 72 assessable patients [56] . Although, the manufacturing success was uniformly high across all three studies (99% for ZUMA-1, 94% for JULIET and 98% for TRANSCEND), the infusion rates (i.e. # infused/# leukapheresed) were significantly different [91% for ZUMA-1 (101/ 111), 70% for JULIET (99/141) and 77% for TRANSCEND (108/ 140)]. Thus, the characteristics of the patients infused may differ between the studies, rendering any comparison difficult. Although these results are very encouraging, it should be noted that the efficacy of CAR-T cells in lymphoma appears to be lower than that observed in ALL for a reason that is not yet well understood (role of the microenvironment?). Moreover, these new drugs often harbor significant toxicities, including cytokine release syndromes and a neurologic toxicity. In the ZUMA-1 study, almost all patients (95%) experienced grade !3 toxicity, mostly hematologic toxicity which was related in part to the conditioning regimen [51] . In addition, cytokine release syndromes were reported, 18% of which were grade 3. A significant proportion of patients received tocilizumab, an anti-IL6 receptor antagonist (43%) and/or systemic corticosteroids (27%). These immunosuppressive treatments did not seem to impact the response. Neurologic toxicity (mainly unspecific encephalopathies) is also frequently observed, including 13% of grade 3. These toxicities are almost always reversible without sequelae and the safety profiles appear to be comparable in the three studies, ZUMA-1, JULIET and TRANSCEND (Table 6 ). Just like 'natural' T cells, CAR-T cells may be inhibited by PD1-PDL1 interaction. Thus, PD1 blockade may further enhance CAR-T cells efficacy. Chong et al. [57] reported the case of a patient with refractory DLBCL progressing after CD19 CAR therapy. Infusion of pembrolizumab at day þ26 after CAR therapy resulted in lymphoma regression and expansion of CAR-T cells. Clinical trials combining CAR-T cells and PD1 blockers are ongoing (NCT02650999 and NCT02926833). Potential combinations to further improve CAR-T cells efficacy are discussed in the review by Khalil et al. [58] .
Finally, CAR-T cells may be effective in lymphoma patients with CNS involvement. A recent publication reported the case of a 68-year-old-woman presenting with refractory DLBCL associated with a brain lesion. This patient experienced a complete response with disappearance of the brain lesion following treatment with JCAR017 [59] .
Hodgkin lymphoma CD30 CAR-T cells were tested in 18 patients with relapse/refractory CD30þ lymphoma (17 HL and 1 cutaneous anaplastic largecell lymphoma) [60] . Seven patients experienced a PR (39%) with a good safety (Table 5) . Several other clinical trials evaluating anti-CD30 CAR-T cells are ongoing.
Discussion
Conclusion CPI, TCE and CAR-T cells represent new types of immunotherapies which offer novel perspectives for the management of patients with lymphoma who have failed conventional therapies. How these different immunotherapies will be integrated in future therapeutic strategies remains to be determined. Each of them presents specific advantages (Table 1) . Furthermore, they may benefit different patients. Finally, these immunotherapies may help each other and work synergistically (e.g. CPI with TCE or CAR-T cells; Tables 3 and 7) . Thus, these new immunotherapies should be seen as complementary rather than competitive. Ongoing and future studies should help identify which of these therapies (or their combination) is more likely to benefit a given patient. This is the beginning of a new and exciting era in which each patient will be offered a 'personalized immunotherapy' based on the status of his tumor and immune system. • Enhance Ag presentation to T cells [113] • Activates T, NK and DC [115] • Inhibits Treg, MDSC and tumor-associated macrophages [115] ADCC, antibody-dependent cellular cytotoxicity; Ag, antigen; APC, antigen-presenting cells; CDC, complement-dependent cytotoxicity; DC, dendritic cells; ICD, immunogenic cell death (i.e. that enhances immunologic reaction against tumor cells); MDSC, myeloid-derived suppressive cells; MHC, major histocompatibility complex; NK, natural killer; TIL, tumor-infiltrating lymphocytes.
